Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to ...

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction ...

The top bidder in the DNA testing firm's bankruptcy auction, Regeneron vows to prioritize the privacy, security, and ethical ...

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

The insolvent genetic analysis company 23andme is taken over by a pharmaceutical company that wants to continue the business ...

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.